Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
RNAi Moves One Step Closer to Clinic
Researchers Tout Delivery Strategies that Have the Potential to Get New Drugs into Trials Sooner
- As more of the human genome is identified and characterized, new frontiers open for therapeutics. “The RNA interference (RNAi) research space continues to explode,” explains Susan Magdaleno, Ph.D., senior manager of scientists, RNAi technologies R&D, Life Technologies. “We are actually expanding into new content. Part of it is a ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.